Thursday, May 14, 2020 10:18:52 AM
In polite posts I have talked about the accelerating migration to home infusion.
ITS A FRIGGING TSUNAMI!! NO OTHER WAY TO SAY IT!!
To manage this volume of growth which impacts all aspects of the organization is extremely challenging (understatement). The management team and board has the needed expertise. The difficulty of the situation is compounded by covid pandemic.
Recent KRMD News
- KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth • Business Wire • 05/01/2024 08:05:00 PM
- KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024 • Business Wire • 04/17/2024 11:00:00 AM
- KORU Medical Systems Announces Successful Appeal in EU Notified Body Review • Business Wire • 04/11/2024 08:05:00 PM
- KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference • Business Wire • 03/18/2024 09:24:00 PM
- KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance • Business Wire • 03/13/2024 08:05:00 PM
- KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic • Business Wire • 03/11/2024 08:05:00 PM
- KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin • Business Wire • 03/06/2024 12:00:00 PM
- KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 • Business Wire • 02/21/2024 12:00:00 PM
- KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference • Business Wire • 11/29/2023 12:00:00 PM
- KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023 • Business Wire • 11/28/2023 01:00:00 PM
- KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System • Business Wire • 11/08/2023 09:10:00 PM
- KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer • Business Wire • 11/08/2023 09:08:00 PM
- KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook • Business Wire • 11/08/2023 09:05:00 PM
- KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes • Business Wire • 11/07/2023 09:05:00 PM
- KORU Medical Systems to Participate in Upcoming Investor Conferences • Business Wire • 11/02/2023 08:05:00 PM
- KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023 • Business Wire • 10/25/2023 08:05:00 PM
- KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference • Business Wire • 10/05/2023 11:05:00 AM
- KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors • Business Wire • 10/04/2023 08:05:00 PM
- KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase • Business Wire • 09/15/2023 12:05:00 PM
- KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook • Business Wire • 08/09/2023 08:05:00 PM
- KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference • Business Wire • 08/08/2023 08:05:00 PM
- KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates • Business Wire • 08/02/2023 09:15:00 PM
- KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023 • Business Wire • 07/31/2023 08:05:00 PM
- KORU Medical Systems Announces Novel Therapies Collaboration for Late-Stage Endocrinological Biologic • Business Wire • 07/27/2023 08:05:00 PM
- KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes • Business Wire • 07/10/2023 11:01:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM